Reduction of Lipase Activity in Product Formulation
Technology
Monoclonal antibodies and other therapeutic proteins produced in mammalian cells, particularly CHO cells, are often formulated with polysorbates (e.g., polysorbate 80 or polysorbate 20) to prevent protein aggregation and increase shelf life. However, these polysorbates degrade over time, compromising drug stability and quality. Lipoprotein lipase (LPL) is an endogenous host cell protein (HCP) that co-purifies with therapeutic proteins and that can degrade polysorbates present in product formulations, negatively impacting product quality. Researchers at the University of Delaware have developed a patented method to reduce the production of LPL in recombinant protein manufacturing. By engineering host cells (e.g., CHO cells) to suppress or eliminate LPL—via siRNA, shRNA, gene knockout, or purification strategies—final products have reduced lipase activity. This innovation enables companies to develop approaches that address product quality issues associated with lipases that degrade polysorbates.
Benefits
- Monoclonal antibody production with improved formulation stability
- Extended shelf life of biopharmaceutical products
- Enhanced safety through reduced polysorbate degradation
- Applicable to various host cells including CHO, NS0, 3T3, and others
- Compatible with diverse therapeutic proteins including enzymes, hormones, and cytokines
- Facilitates regulatory compliance by reducing problematic HCPs in final formulations
Applications
- Drug delivery systems